Distinction of acute myeloid leukemia with low blast count from pediatric myelodysplastic syndrome is clinically important
Chan, G.C.F.; Wang, W.; Raimondi, S.; Behm, F.; Krance, R.; Head, D.
Blood 84(10 Suppl 1): 315A
1994
ISSN/ISBN: 0006-4971 Accession: 030969423
Full Text Article emailed within 1 workday: $29.90
Related References
Kenealy, M.; Patton, N.; Filshie, R.; Nicol, A.; Ho, S-Jing.; Hertzberg, M.; Mills, T.; Prosser, I.; Link, E.; Cowan, L.; Zannino, D.; Seymour, J.F. 2017: Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML) Leukemia and Lymphoma 58(2): 298-307Chan, G.C.; Wang, W.C.; Raimondi, S.C.; Behm, F.G.; Krance, R.A.; Chen, G.; Freiberg, A.; Ingram, L.; Butler, D.; Head, D.R. 1997: Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count Leukemia 11(2): 206-211
Prebet, T.; Charbonnier, A.; Gelsi-Boyer, V.ér.; Mozziconacci, M.J.; Blaise, D.; Vey, N. 2013: Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure Leukemia and Lymphoma 54(7): 1538-1540
Sébert, M.; Renneville, A.; Bally, C.éc.; Peterlin, P.; Beyne-Rauzy, O.; Legros, L.; Gourin, M.-P.; Sanhes, L.; Wattel, E.; Gyan, E.; Park, S.; Stamatoullas, A.; Banos, A.; Laribi, K.; Jueliger, S.; Bevan, L.; Chermat, F.; Sapena, R.; Nibourel, O.; Chaffaut, C.; Chevret, S.; Preudhomme, C.; Adès, L.; Fenaux, P. 2019: A phase Ii study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure Haematologica 104(8): 1565-1571
Solly, F.ço.; Koering, C.; Mohamed, A.M.; Maucort-Boulch, D.; Robert, G.; Auberger, P.; Flandrin-Gresta, P.; Adès, L.; Fenaux, P.; Kosmider, O.; Tavernier-Tardy, E.; Cornillon, J.ér.ôm.; Guyotat, D.; Campos, L.; Mortreux, F.; Wattel, E. 2017: An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23(12): 3025-3034
Nakase, K.; Kita, K.; Kyo, T.; Katayama, N. 2017: High expression of interleukin-2 receptor α-chain (CD25) in myelodysplastic syndrome preceding acute myeloid leukemia and chronic myeloid leukemia in myeloid blast crisis Leukemia and Lymphoma 58(5): 1268-1270
Voso, M.Teresa.; Niscola, P.; Piciocchi, A.; Fianchi, L.; Maurillo, L.; Musto, P.; Pagano, L.; Mansueto, G.; Criscuolo, M.; Aloe-Spiriti, M.Antonietta.; Buccisano, F.; Venditti, A.; Tendas, A.; Piccioni, A.Lina.; Zini, G.; Latagliata, R.; Filardi, N.; Fragasso, A.; Fenu, S.; Breccia, M. 2016: Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia European Journal of Haematology 96(4): 344-351
Jabbour, E.; Garcia-Manero, G.; Cortes, J.; Ravandi, F.; Plunkett, W.; Gandhi, V.; Faderl, S.; O'Brien, S.; Borthakur, G.; Kadia, T.; Burger, J.; Konopleva, M.; Brandt, M.; Huang, X.; Kantarjian, H. 2012: Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia Clinical Lymphoma Myeloma and Leukemia 12(4): 244-251
Head, D.R.; Chan, G.C.F.; Wang, W.; Behm, F.; Raimondi, S.; Krance, R.; Butler, D. 1995: Acute myeloblastic leukemia with a low blast count is distinct from myelodysplastic syndrome Modern Pathology 8(1): 112A
Mozessohn, L.; Cheung, M.C.; Mittmann, N.; Earle, C.C.; Liu, N.; Buckstein, R. 2021: Real-World Costs of Azacitidine Treatment in Patients with Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia Jco Oncology Practice 17(4): E517-E525
Chen, X.; Othus, M.; Wood, B.L.; Walter, R.B.; Becker, P.S.; Percival, M-Elizabeth.; Abkowitz, J.L.; Appelbaum, F.R.; Estey, E.H. 2020: Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia Leukemia and Lymphoma 2020: 1-7
Estey, E.H.; Keating, M.J.; Dixon, D.O.; Trujillo, J.M.; McCredie, K.B.; Freireich, E.J. 1987: Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia Hematologic Pathology 1(4): 203-208
Kenealy, M.; Hertzberg, M.; Benson, W.; Taylor, K.; Cunningham, I.; Stevenson, W.; Hiwase, D.; Eek, R.; Zantomio, D.; Jong, S.; Wall, M.; Blombery, P.; Gerber, T.; Debrincat, M.; Zannino, D.; Seymour, J.F. 2019: Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome and low blast acute myeloid leukemia Haematologica 104(4): 700-709
Baumann, I.; Harms, H.; Kuse, R.; Feller, A.C.; Müller-Hermelink, H.K. 1990: Pattern analytic investigations of blast cells in myelodysplastic syndrome and secondary acute myeloid leukemia Verhandlungen der Deutschen Gesellschaft für Pathologie 74: 135-138
Voso, M.T.; Leone, G.; Piciocchi, A.; Fianchi, L.; Santarone, S.; Candoni, A.; Criscuolo, M.; Masciulli, A.; Cerqui, E.; Molteni, A.; Finelli, C.; Parma, M.; Poloni, A.; Carella, A.M.; Spina, F.; Cortelezzi, A.; Salvi, F.; Alessandrino, E.P.; Rambaldi, A.; Sica, S. 2017: Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study Annals of Oncology: Official Journal of the European Society for Medical Oncology 28(7): 1547-1553
Karimi, M.; Nilsson, C.; Dimitriou, M.; Jansson, M.; Matsson, H.; Unneberg, P.; Lehmann, S.ör.; Kere, J.; Hellström-Lindberg, E. 2015: High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia Haematologica 100(6): E223-E225
Mozessohn, L.; Cheung, M.C.; Fallahpour, S.; Gill, T.; Maloul, A.; Zhang, L.; Lau, O.; Buckstein, R. 2018: Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada British Journal of Haematology 181(6): 803-815
Suzuki, K.; Ohishi, K.; Sekine, T.; Masuya, M.; Katayama, N. 2007: Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to myelodysplastic syndrome treated with methylprednisolone International Journal of Hematology 85(4): 344-349
Drexler, B.; Tzankov, A.; Martinez, M.; Baerlocher, S.; Passweg, J.R.; Dirnhofer, S.; Tsakiris, D.A.; Dirks, J. 2021: Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56 International Journal of Laboratory Hematology 43(5): 1078-1084
DiNardo, C.D.; Garcia-Manero, G.; Pierce, S.; Nazha, A.; Bueso-Ramos, C.; Jabbour, E.; Ravandi, F.; Cortes, J.; Kantarjian, H. 2016: Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) American Journal of Hematology 91(2): 227-232